In work led by @bdadonaite @khdcrawford @CaelanRadford, we develop pseudovirus system to deep mutational scan full #SARSCoV2 spike: https://t.co/O6MGHXVWdS TLDR: can now safely measure how all mutations to viral entry proteins affect antibody neutralization. 🧵 below (1/n)

We first report the effects of all mutations on ACE2 binding affinity and protein folding stability. Interactive versions of these maps (together maps from prior SARS2 variants), are available here: https://t.co/u0GpKYop3g Like prior maps, we see wide tolerance to mutation.

Our newest study is up, where we report deep mutational scanning data in the Omicron BA.1 and BA.2 receptor-binding domains

New paper from @jbloom_lab about the importance of ACE2 expression on target cells on SARS-CoV-2 neutralization - thanks #HAARVI participants for contributing to these studies.

In new study led by @dbacsik, we show single influenza-infected cells produce wildly different numbers of viral progeny: https://t.co/mZSRW3k2iw Surprisingly, cells that transcribe the most viral mRNA are NOT ones that produce the most progeny virions. Explanatory 🧵 below

In new study, we examine how target cell ACE2 expression affects #SARSCoV2 neutralization https://t.co/47RTQ5aeSS We find high-ACE2 cells emphasize role of RBD antibodies in serum & lower ACE2 cells reveal more neutralization by antibodies to other regions of spike. 🧵 below:

Was a pleasure to contribute to this very cool study looking at how heterologous boosting elicits new versus boosted original antigenic sin antibody responses in mice from @victora_lab !

Our latest review is now out in @BiochemistryACS! In this Perspective, we discuss the importance of InDels in protein evolution, whether in nature or the test tube, and strongly advocate their potential for protein engineering. @tokuriki_lab

We have a position in the Bloom lab for a research tech interested in using deep mutational scanning to study evolution of viruses including SARS-CoV-2 & influenza: https://t.co/o6yLQZfkQY (And while this ad is for a tech, we are always open to inquiries from postdoc candidates)

If you’re into viral, antibody, or protein evolution, check out the 🌟 Starr lab 🌟! Can confirm that @tylernstarr is one of the most brilliant, fun, and supportive scientists out there! Already envious of the new folks who get to work with you!

Excited to share our work on epistasis shaping the evolution of SARS-CoV-2 BA.1 — had a blast working on this with @AliefMoulana @ThomasDupic Jeffrey Chang, @MichaelMDesai & @jbloom_lab:

What a special moment: the #COVID19 vaccine we designed with @coronalexington @KingLabIPD has met its primary endpoints in the phase 3 clinical trial run by SK bioscience!!! @HHMINEWS @UWproteindesign @UWBiochemistry 1/4 https://t.co/1hJbfprxhE

Thanks @bblarsen1 for the tip!

Love these Washington state-inspired palettes!

Our work on the stabilization of flu NA is officially published in @NatureComms! Large congrats and thanks to Julia Lederhofer, @kanekiyom, @KingLabIPD, @veeslerlab, @OliverActon3, @BarneyGrahamMD and many more

Wanted to add to @DrNeeltje's nice summary about the recent pre-print on @Acoh92 @bjorkmanlab's mosaic RBD nanoparticle vaccine, which at least in animals induces "broader" antibody immunity to #SARSCoV2 variants and other SARS-related CoVs: https://t.co/YHMnJjPOe6 (1/n)

Cool graphic from @Nat_Lash vividly illustrating potential for continuing evolution in #SARSCoV2 receptor-binding domain (RBD), which is key target of antibodies. There are 15 RBD mutations in Omicron (BA.1), which seems like a lot! But... (1/3)

(10/n) In the future, it would be good to understand the specificity of the antibody response to Omicron and which mutations might erode that immunity.

(9/n) And thanks to our collaborators @sigallab @HelenChuMD Cate Speake and their teams, including @KhadijaKhan24 @SkiClimbSciNick @jenni_logue. (And of course @jbloom_lab mates @tylernstarr and @eguia_rachel) It was so fun to work with you all!